MA46024A - Vaccin contre le virus de l'herpès simplex - Google Patents
Vaccin contre le virus de l'herpès simplexInfo
- Publication number
- MA46024A MA46024A MA046024A MA46024A MA46024A MA 46024 A MA46024 A MA 46024A MA 046024 A MA046024 A MA 046024A MA 46024 A MA46024 A MA 46024A MA 46024 A MA46024 A MA 46024A
- Authority
- MA
- Morocco
- Prior art keywords
- herpes simplex
- simplex vaccine
- vaccine
- herpes
- simplex
- Prior art date
Links
- 229940124725 herpes simplex vaccine Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6018—Lipids, e.g. in lipopeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562245159P | 2015-10-22 | 2015-10-22 | |
| US201562245031P | 2015-10-22 | 2015-10-22 | |
| US201562247576P | 2015-10-28 | 2015-10-28 | |
| US201562248252P | 2015-10-29 | 2015-10-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA46024A true MA46024A (fr) | 2019-07-03 |
Family
ID=58558127
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA046024A MA46024A (fr) | 2015-10-22 | 2016-10-21 | Vaccin contre le virus de l'herpès simplex |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US20180303929A1 (fr) |
| EP (1) | EP3365009A4 (fr) |
| JP (2) | JP2018536023A (fr) |
| KR (1) | KR20180096593A (fr) |
| CN (1) | CN108472355A (fr) |
| AU (2) | AU2016342049B2 (fr) |
| BR (1) | BR112018008090A2 (fr) |
| CA (1) | CA3002822A1 (fr) |
| CL (1) | CL2018001056A1 (fr) |
| CO (1) | CO2018005258A2 (fr) |
| EA (1) | EA201890999A1 (fr) |
| IL (1) | IL258833A (fr) |
| MA (1) | MA46024A (fr) |
| MX (1) | MX2018004918A (fr) |
| PE (1) | PE20181531A1 (fr) |
| PH (1) | PH12018500855A1 (fr) |
| SG (1) | SG11201803365RA (fr) |
| TN (1) | TN2018000155A1 (fr) |
| WO (1) | WO2017070623A1 (fr) |
Families Citing this family (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| BR112016024644A2 (pt) | 2014-04-23 | 2017-10-10 | Modernatx Inc | vacinas de ácido nucleico |
| US11364292B2 (en) | 2015-07-21 | 2022-06-21 | Modernatx, Inc. | CHIKV RNA vaccines |
| EP3324979B1 (fr) | 2015-07-21 | 2022-10-12 | ModernaTX, Inc. | Vaccins contre une maladie infectieuse |
| US11564893B2 (en) | 2015-08-17 | 2023-01-31 | Modernatx, Inc. | Methods for preparing particles and related compositions |
| CA3002912A1 (fr) | 2015-10-22 | 2017-04-27 | Modernatx, Inc. | Vaccins a base d'acide nucleique contre le virus varicelle-zona (vzv) |
| WO2017070624A1 (fr) | 2015-10-22 | 2017-04-27 | Modernatx, Inc. | Vaccins contre des maladies tropicales |
| AU2016342045A1 (en) | 2015-10-22 | 2018-06-07 | Modernatx, Inc. | Human cytomegalovirus vaccine |
| MA45209A (fr) | 2015-10-22 | 2019-04-17 | Modernatx Inc | Vaccins contre les maladies sexuellement transmissibles |
| EP4349405A3 (fr) | 2015-10-22 | 2024-06-19 | ModernaTX, Inc. | Vaccins contre le virus respiratoire |
| EP3964200A1 (fr) | 2015-12-10 | 2022-03-09 | ModernaTX, Inc. | Compositions et procédés permettant d'administrer des agents thérapeutiques |
| US10465190B1 (en) | 2015-12-23 | 2019-11-05 | Modernatx, Inc. | In vitro transcription methods and constructs |
| MA45051A (fr) | 2016-05-18 | 2019-03-27 | Modernatx Inc | Polynucléotides codant la relaxine |
| EP4166666A1 (fr) | 2016-09-14 | 2023-04-19 | ModernaTX, Inc. | Compositions d'arn à pureté élevée et leurs procédés de préparation |
| EP3528821A4 (fr) | 2016-10-21 | 2020-07-01 | ModernaTX, Inc. | Vaccin contre le cytomégalovirus humain |
| WO2018089851A2 (fr) | 2016-11-11 | 2018-05-17 | Modernatx, Inc. | Vaccin antigrippal |
| US11103578B2 (en) | 2016-12-08 | 2021-08-31 | Modernatx, Inc. | Respiratory virus nucleic acid vaccines |
| US11384352B2 (en) | 2016-12-13 | 2022-07-12 | Modernatx, Inc. | RNA affinity purification |
| EP3582790A4 (fr) | 2017-02-16 | 2020-11-25 | ModernaTX, Inc. | Compositions immunogènes très puissantes |
| EP3609534A4 (fr) | 2017-03-15 | 2021-01-13 | ModernaTX, Inc. | Vaccin à large spectre contre le virus de la grippe |
| WO2018170256A1 (fr) * | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Vaccin contre le virus de l'herpès simplex |
| MA47787A (fr) | 2017-03-15 | 2020-01-22 | Modernatx Inc | Vaccin contre le virus respiratoire syncytial |
| WO2018170270A1 (fr) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Vaccin contre le virus varicelle-zona |
| WO2018170347A1 (fr) | 2017-03-17 | 2018-09-20 | Modernatx, Inc. | Vaccins à base d'arn contre des maladies zoonotiques |
| MA48047A (fr) | 2017-04-05 | 2020-02-12 | Modernatx Inc | Réduction ou élimination de réponses immunitaires à des protéines thérapeutiques administrées par voie non intraveineuse, par exemple par voie sous-cutanée |
| MA49463A (fr) * | 2017-04-26 | 2021-05-05 | Modernatx Inc | Vaccin contre le virus de l'herpès simplex |
| US11160860B2 (en) * | 2017-04-26 | 2021-11-02 | Merck Sharp & Dohme Corp. | HSV antigenic peptides and HSV protein vaccines |
| EP3638215A4 (fr) | 2017-06-15 | 2021-03-24 | Modernatx, Inc. | Formulations d'arn |
| EP4242223A3 (fr) * | 2017-08-17 | 2024-03-13 | The Trustees of The University of Pennsylvania | Vaccins à arnm modifiés codant pour des glycoprotéines du virus de l'herpès simplex et leurs utilisations |
| US11866696B2 (en) | 2017-08-18 | 2024-01-09 | Modernatx, Inc. | Analytical HPLC methods |
| MA49913A (fr) | 2017-08-18 | 2021-05-05 | Modernatx Inc | Variants d'arn polymérase |
| US11912982B2 (en) | 2017-08-18 | 2024-02-27 | Modernatx, Inc. | Methods for HPLC analysis |
| AU2018326799A1 (en) | 2017-08-31 | 2020-02-27 | Modernatx, Inc. | Methods of making lipid nanoparticles |
| US10653767B2 (en) | 2017-09-14 | 2020-05-19 | Modernatx, Inc. | Zika virus MRNA vaccines |
| WO2019148101A1 (fr) | 2018-01-29 | 2019-08-01 | Modernatx, Inc. | Vaccins à base d'arn contre le vrs |
| CN113271926A (zh) | 2018-09-20 | 2021-08-17 | 摩登纳特斯有限公司 | 脂质纳米颗粒的制备及其施用方法 |
| US11351242B1 (en) | 2019-02-12 | 2022-06-07 | Modernatx, Inc. | HMPV/hPIV3 mRNA vaccine composition |
| CN109701008B (zh) * | 2019-02-18 | 2022-06-21 | 山东兴瑞生物科技有限公司 | 针对单纯疱疹病毒的治疗性dc复合疫苗及其制备方法 |
| US11851694B1 (en) | 2019-02-20 | 2023-12-26 | Modernatx, Inc. | High fidelity in vitro transcription |
| JP2022521094A (ja) | 2019-02-20 | 2022-04-05 | モデルナティエックス インコーポレイテッド | 共転写キャッピング用ｒｎａポリメラーゼバリアント |
| WO2020190750A1 (fr) | 2019-03-15 | 2020-09-24 | Modernatx, Inc. | Vaccins à base d'arn contre le vih |
| EP3999093A4 (fr) * | 2019-07-19 | 2023-11-22 | Merck Sharp & Dohme LLC | Polypeptides de glycoprotéines e antigéniques, compositions et leurs procédés d'utilisation |
| AU2020318680A1 (en) * | 2019-07-21 | 2022-02-17 | Glaxosmithkline Biologicals Sa | Therapeutic viral vaccine |
| WO2021197589A1 (fr) * | 2020-03-31 | 2021-10-07 | BioNTech SE | Traitement faisant appel à un arn non immunogène pour la vaccination d'antigènes |
| CA3174215A1 (fr) | 2020-04-22 | 2021-10-28 | Ugur Sahin | Vaccin contre un coronavirus |
| KR20230034333A (ko) | 2020-07-02 | 2023-03-09 | 라이프 테크놀로지스 코포레이션 | 트리뉴클레오티드 캡 유사체, 제조 및 이의 용도 |
| US11406703B2 (en) | 2020-08-25 | 2022-08-09 | Modernatx, Inc. | Human cytomegalovirus vaccine |
| US11524023B2 (en) | 2021-02-19 | 2022-12-13 | Modernatx, Inc. | Lipid nanoparticle compositions and methods of formulating the same |
| WO2022189634A1 (fr) * | 2021-03-11 | 2022-09-15 | Redbiotec Ag | Compositions vaccinales et procédés de traitement du vhs |
| EP4395748A1 (fr) | 2021-09-03 | 2024-07-10 | CureVac SE | Nouvelles nanoparticules lipidiques pour l'administration d'acides nucléiques |
| EP4422698A1 (fr) | 2021-10-29 | 2024-09-04 | CureVac SE | Arn circulaire amélioré pour exprimer des protéines thérapeutiques |
| WO2023107999A2 (fr) | 2021-12-08 | 2023-06-15 | Modernatx, Inc. | Vaccins à arnm contre le virus de l'herpès simplex |
| WO2023147090A1 (fr) * | 2022-01-27 | 2023-08-03 | BioNTech SE | Compositions pharmaceutiques pour administration d'antigènes du virus herpès simplex et méthodes associées |
| WO2023144330A1 (fr) | 2022-01-28 | 2023-08-03 | CureVac SE | Inhibiteurs de facteurs de transcription codés par un acide nucleique |
| WO2023227608A1 (fr) | 2022-05-25 | 2023-11-30 | Glaxosmithkline Biologicals Sa | Vaccin à base d'acide nucléique codant pour un polypeptide antigénique fimh d'escherichia coli |
| US11878055B1 (en) | 2022-06-26 | 2024-01-23 | BioNTech SE | Coronavirus vaccine |
| US20240156949A1 (en) | 2022-10-28 | 2024-05-16 | Glaxosmithkline Biologicals Sa | Nucleic Acid Based Vaccine |
| WO2024131664A1 (fr) * | 2022-12-19 | 2024-06-27 | 南京奥罗生物科技有限公司 | Vaccin contre le virus de l'herpès simplex et son utilisation |
| WO2024163465A1 (fr) | 2023-01-30 | 2024-08-08 | Modernatx, Inc. | Vaccins à arnm du virus d'epstein-barr |
| WO2024184500A1 (fr) | 2023-03-08 | 2024-09-12 | CureVac SE | Nouvelles formulations de nanoparticules lipidiques pour l'administration d'acides nucléiques |
Family Cites Families (91)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5703055A (en) * | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| WO1993001301A1 (fr) * | 1991-07-05 | 1993-01-21 | The Penn State Research Foundation | Proteines de regulation antivirales mutantes |
| GB9406498D0 (en) * | 1994-03-31 | 1994-05-25 | Smithkline Beecham Biolog | Novel compounds |
| US7094767B2 (en) * | 1994-07-22 | 2006-08-22 | Merck & Co., Inc. | Polynucleotide herpes virus vaccine |
| US5795587A (en) | 1995-01-23 | 1998-08-18 | University Of Pittsburgh | Stable lipid-comprising drug delivery complexes and methods for their production |
| US6214966B1 (en) | 1996-09-26 | 2001-04-10 | Shearwater Corporation | Soluble, degradable poly(ethylene glycol) derivatives for controllable release of bound molecules into solution |
| EP0948508A4 (fr) * | 1996-11-04 | 2001-11-07 | Smithkline Beecham Corp | Nouvelles sequences codantes pour le virus herpes simplex de type 2 |
| JP2003512305A (ja) * | 1999-09-30 | 2003-04-02 | ユニバーシティ オブ ワシントン | 免疫学的に重要な単純疱疹ウイルス抗原 |
| AU2001275423B2 (en) * | 2000-06-09 | 2007-01-11 | Regulon, Inc. | Encapsulation of polynucleotides and drugs into targeted liposomes |
| US6998115B2 (en) | 2000-10-10 | 2006-02-14 | Massachusetts Institute Of Technology | Biodegradable poly(β-amino esters) and uses thereof |
| US7708915B2 (en) | 2004-05-06 | 2010-05-04 | Castor Trevor P | Polymer microspheres/nanospheres and encapsulating therapeutic proteins therein |
| DK1857122T3 (da) | 2001-06-05 | 2011-03-21 | Curevac Gmbh | Stabiliseret mRNA med forøget G/C-indhold, kodende for et viralt antigen |
| EP1412065A2 (fr) | 2001-07-27 | 2004-04-28 | President And Fellows Of Harvard College | Appareil et procedes de melange de flux laminaires |
| WO2003028657A2 (fr) | 2001-10-03 | 2003-04-10 | The Johns Hopkins University | Compositions pour therapie genique orale et procedes d'utilisation associes |
| WO2003092665A2 (fr) | 2002-05-02 | 2003-11-13 | Massachusetts Eye And Ear Infirmary | Systemes oculaires de distribution de medicament et utilisation associee |
| CA2546616A1 (fr) * | 2003-11-21 | 2005-06-09 | Alza Corporation | Administration de genes par l'intermediaire de complexe liposome/adn avec modification de surface peg clivable |
| WO2005072710A2 (fr) | 2004-01-28 | 2005-08-11 | Johns Hopkins University | Medicaments et particules de transport de genes se deplaçant rapidement a travers les barrieres muqueuses |
| WO2006097793A2 (fr) | 2004-04-15 | 2006-09-21 | Chiasma, Ltd. | Compositions capables de faciliter la penetration a travers une barriere biologique |
| ES2407979T3 (es) | 2004-12-10 | 2013-06-17 | Kala Pharmaceuticals, Inc. | Copolímeros de bloques de poli(éter-anhídrido) funcionalizados |
| EP1907444B1 (fr) | 2005-04-01 | 2009-08-19 | Intezyne Technologies Incorporated | Micelles de polymere servant a la delivrance de medicaments |
| EP1885403B1 (fr) | 2005-04-12 | 2013-05-08 | Nektar Therapeutics | Conjugués de la lysostaphine et du poly(éthylène glycol) |
| AU2006259225B2 (en) | 2005-06-16 | 2012-05-31 | Nektar Therapeutics | Conjugates having a degradable linkage and polymeric reagents useful in preparing such conjugates |
| US9149543B2 (en) * | 2005-12-15 | 2015-10-06 | The Trustees Of The University Of Pennsylvania | Methods and models for rapid, widespread delivery of genetic material to the CNS using non-viral, cationic lipid-mediated vectors |
| CN103030801B (zh) | 2006-02-21 | 2015-07-22 | 尼克塔治疗公司 | 嵌段可降解聚合物及由其制备的轭合物 |
| CA2652280C (fr) | 2006-05-15 | 2014-01-28 | Massachusetts Institute Of Technology | Polymeres pour particules fonctionnelles |
| AU2007252296A1 (en) * | 2006-05-19 | 2007-11-29 | The Walter And Eliza Hall Institute Of Medical Research | Immunogenic compositions |
| JP5872755B2 (ja) * | 2006-07-20 | 2016-03-01 | バイカル インコーポレイテッド | 抗ｈｓｖ−２ワクチン接種のための組成物および方法 |
| DE602007012559D1 (de) | 2006-09-08 | 2011-03-31 | Univ Johns Hopkins | H die schleimhaut |
| AU2007339280B2 (en) | 2006-12-21 | 2013-12-05 | Stryker Corporation | Sustained-release formulations comprising crystals, macromolecular gels, and particulate suspensions of biologic agents |
| US8877206B2 (en) * | 2007-03-22 | 2014-11-04 | Pds Biotechnology Corporation | Stimulation of an immune response by cationic lipids |
| EP2644192B1 (fr) | 2007-09-28 | 2017-05-10 | Pfizer Inc | Ciblage de cellules de cancer utilisant des nanoparticules |
| ES2765240T3 (es) | 2008-06-16 | 2020-06-08 | Pfizer | Nanopartículas poliméricas cargadas de fármaco y procedimientos de fabricación y uso de las mismas |
| JP2011525180A (ja) | 2008-06-16 | 2011-09-15 | バインド バイオサイエンシズ インコーポレイテッド | 治療的標的化ナノ粒子の製作に用いるためのジブロックコポリマーで官能化された標的薬の製造方法 |
| WO2010005725A2 (fr) | 2008-06-16 | 2010-01-14 | Bind Biosciences, Inc. | Nanoparticules polymères thérapeutiques comprenant des alcaloïdes vinca et procédés de fabrication et d’utilisation associés |
| US8613951B2 (en) | 2008-06-16 | 2013-12-24 | Bind Therapeutics, Inc. | Therapeutic polymeric nanoparticles with mTor inhibitors and methods of making and using same |
| WO2010030763A2 (fr) | 2008-09-10 | 2010-03-18 | Bind Biosciences, Inc. | Fabrication de nanoparticles à rendement élevé |
| JP2012512175A (ja) | 2008-12-15 | 2012-05-31 | バインド バイオサイエンシズ インコーポレイテッド | 治療薬を徐放するための長時間循環性ナノ粒子 |
| JP5622254B2 (ja) | 2009-03-31 | 2014-11-12 | 国立大学法人東京大学 | 二本鎖リボ核酸ポリイオンコンプレックス |
| WO2010127159A2 (fr) | 2009-04-30 | 2010-11-04 | Intezyne Technologies, Incorporated | Micelles polymères pour l'encapsulation de polynucléotides |
| JP5823405B2 (ja) | 2009-11-04 | 2015-11-25 | ザ ユニバーシティ オブ ブリティッシュ コロンビア | 核酸含有脂質粒子および関連方法 |
| WO2011084521A2 (fr) | 2009-12-15 | 2011-07-14 | Bind Biosciences, Inc. | Nanoparticules polymères thérapeutiques comportant de l'épothilone et leurs procédés de fabrication et d'utilisation |
| JP5965844B2 (ja) | 2009-12-15 | 2016-08-10 | バインド セラピューティックス インコーポレイテッド | 高いガラス転移温度または高分子量のコポリマーを有する治療用ポリマーナノ粒子組成物 |
| WO2011084518A2 (fr) | 2009-12-15 | 2011-07-14 | Bind Biosciences, Inc. | Nanoparticules polymères thérapeutiques comprenant de corticostéroïdes, et procédés pour les fabriquer et les utiliser |
| PT2525815E (pt) | 2010-01-24 | 2015-03-05 | Novartis Ag | Micropartículas de polímero biodegradável irradiadas |
| US9089537B2 (en) * | 2010-02-26 | 2015-07-28 | The Trustees Of The University Of Pennslyvania | Subunit vaccines for herpes viruses and methods of use |
| WO2011119262A1 (fr) | 2010-03-26 | 2011-09-29 | Cerulean Pharma Inc. | Procédés et systèmes de production de nanoparticules |
| US20110262491A1 (en) | 2010-04-12 | 2011-10-27 | Selecta Biosciences, Inc. | Emulsions and methods of making nanocarriers |
| WO2011149733A2 (fr) | 2010-05-24 | 2011-12-01 | Merck Sharp & Dohme Corp. | Nouveaux lipides cationiques alcools aminés pour l'administration d'oligonucléotides |
| WO2011163483A2 (fr) | 2010-06-25 | 2011-12-29 | Massachusetts Institute Of Technology | Polymères pour des biomatériaux et des agents thérapeutiques |
| BR112013000392B8 (pt) * | 2010-07-06 | 2022-10-04 | Novartis Ag | Composição farmacêutica contendo partícula de distribuição semelhante a vírion para moléculas de rna autorreplicantes e seu uso |
| WO2012039979A2 (fr) | 2010-09-10 | 2012-03-29 | The Johns Hopkins University | Diffusion rapide de grosses nanoparticules polymères dans le cerveau de mammifères |
| TR201903651T4 (tr) * | 2010-10-11 | 2019-04-22 | Glaxosmithkline Biologicals Sa | Antijen uygulama platformları. |
| US20150056300A1 (en) | 2010-10-22 | 2015-02-26 | Bind Therapeutics, Inc. | Therapeutic nanoparticles with high molecular weight copolymers |
| CA3054532C (fr) | 2010-11-05 | 2022-07-12 | The Johns Hopkins University | Compositions et procedes visant a une reduction de la mucoadherence |
| US20120189700A1 (en) | 2011-01-19 | 2012-07-26 | Zoraida Aguilar | Nanoparticle Based Immunological Stimulation |
| US9243041B2 (en) * | 2011-01-31 | 2016-01-26 | The Trustees Of The University Of Pennsylvania | Nucleic acid molecules encoding novel herpes antigens, vaccine comprising the same, and methods of use thereof |
| US20140066363A1 (en) | 2011-02-07 | 2014-03-06 | Arun K. Bhunia | Carbohydrate nanoparticles for prolonged efficacy of antimicrobial peptide |
| CA2831471C (fr) | 2011-03-31 | 2020-02-25 | Ingell Technologies Holding B.V. | Compositions biodegradables appropriees pour une liberation controlee |
| WO2012131104A2 (fr) | 2011-03-31 | 2012-10-04 | Ingell Technologies Holding B.V. | Compositions biodégradables adaptées à une libération contrôlée |
| US8691750B2 (en) | 2011-05-17 | 2014-04-08 | Axolabs Gmbh | Lipids and compositions for intracellular delivery of biologically active compounds |
| US20140308363A1 (en) | 2011-05-31 | 2014-10-16 | Bind Therapeutics, Inc. | Drug loaded polymeric nanoparticles and methods of making and using same |
| SG10201605537XA (en) * | 2011-07-06 | 2016-09-29 | Novartis Ag | Liposomes having useful n:p ratio for delivery of rna molecules |
| BR112014001050B1 (pt) | 2011-07-21 | 2017-12-05 | Croda International Plc | Polyester polyester block polymer, method for the preparation of the same, composition, controlled release and personal care products, and method for preparing a gel composition |
| MX2014001971A (es) | 2011-08-26 | 2014-03-31 | Arrowhead Res Corp | Polimeros de poli(vinilester) para suministro de acido nucleico in vivo. |
| CA2845845A1 (fr) | 2011-08-31 | 2013-03-07 | Mallinckrodt Llc | Modification de nanoparticules de peg avec des h-phosphonates |
| WO2013044219A1 (fr) | 2011-09-22 | 2013-03-28 | Bind Biosciences | Méthodes de traitement de cancers au moyen de nanoparticules thérapeutiques |
| US9375388B2 (en) | 2011-09-23 | 2016-06-28 | Indian Institute Of Technology, Bombay | Nanoparticle based cosmetic composition |
| MX2014004214A (es) * | 2011-10-11 | 2014-05-07 | Novartis Ag | Moleculas de acido ribonucleico policistronicas auto-replicantes recombinantes. |
| CN103987847B (zh) | 2011-10-18 | 2017-06-16 | 迪克纳制药公司 | 胺阳离子脂质及其用途 |
| UA119028C2 (uk) | 2011-10-27 | 2019-04-25 | Массачусеттс Інстітьют Оф Текнолоджі | Функціоналізовані на n-кінці амінокислотні похідні, здатні утворювати мікросфери, що інкапсулюють лікарський засіб |
| WO2013078199A2 (fr) | 2011-11-23 | 2013-05-30 | Children's Medical Center Corporation | Méthodes pour une administration in vivo améliorée d'arn synthétiques modifiés |
| RS63244B1 (sr) * | 2011-12-16 | 2022-06-30 | Modernatx Inc | Kompozicije modifikovane mrna |
| CA2863632C (fr) | 2012-01-19 | 2017-07-11 | The Johns Hopkins University | Formulations de nanoparticules presentant une penetration amelioree dans les muqueuses |
| WO2013113326A1 (fr) * | 2012-01-31 | 2013-08-08 | Curevac Gmbh | Composition pharmaceutique comprenant un complexe support polymère - charge et au moins un antigène de protéine ou de peptide |
| AU2013214799B2 (en) | 2012-02-03 | 2016-05-12 | Rutgers, The State Of University Of New Jersey | Polymeric biomaterials derived from phenolic monomers and their medical uses |
| WO2013120052A1 (fr) | 2012-02-10 | 2013-08-15 | E. I. Du Pont De Nemours And Company | Préparation, purification et utilisation de copolymères à deux blocs à χ élevé |
| WO2013143555A1 (fr) * | 2012-03-26 | 2013-10-03 | Biontech Ag | Formulation d'arn pour immunothérapie |
| EA201492055A1 (ru) * | 2012-06-08 | 2015-11-30 | Шир Хьюман Дженетик Терапис, Инк. | ИНГАЛЯЦИОННАЯ ДОСТАВКА мРНК В НЕЛЕГОЧНЫЕ КЛЕТКИ-МИШЕНИ |
| WO2014089486A1 (fr) * | 2012-12-07 | 2014-06-12 | Shire Human Genetic Therapies, Inc. | Nanoparticules lipidiques pour administration de marn |
| EP2931319B1 (fr) * | 2012-12-13 | 2019-08-21 | ModernaTX, Inc. | Molécules d'acide nucléique modifiées et leurs utilisations |
| AU2014239184B2 (en) * | 2013-03-14 | 2018-11-08 | Translate Bio, Inc. | Methods and compositions for delivering mRNA coded antibodies |
| US20160032273A1 (en) | 2013-03-15 | 2016-02-04 | Moderna Therapeutics, Inc. | Characterization of mrna molecules |
| US10590161B2 (en) | 2013-03-15 | 2020-03-17 | Modernatx, Inc. | Ion exchange purification of mRNA |
| WO2014144711A1 (fr) | 2013-03-15 | 2014-09-18 | Moderna Therapeutics, Inc. | Analyse de l'hétérogénéité et de la stabilité d'arnm |
| WO2014152027A1 (fr) | 2013-03-15 | 2014-09-25 | Moderna Therapeutics, Inc. | Procédés de fabrication pour la production de transcrits d'arn |
| EP2972360B1 (fr) * | 2013-03-15 | 2018-03-07 | Translate Bio, Inc. | Stimulation synergique de l'administration d'acides nucléiques par le biais de formulations mélangées |
| WO2014152030A1 (fr) | 2013-03-15 | 2014-09-25 | Moderna Therapeutics, Inc. | Elimination de fragments d'adn dans des procédés de production d'arnm |
| US11377470B2 (en) | 2013-03-15 | 2022-07-05 | Modernatx, Inc. | Ribonucleic acid purification |
| TW201534578A (zh) * | 2013-07-08 | 2015-09-16 | Daiichi Sankyo Co Ltd | 新穎脂質 |
| BR112016024644A2 (pt) * | 2014-04-23 | 2017-10-10 | Modernatx Inc | vacinas de ácido nucleico |
| US12098380B2 (en) * | 2017-06-05 | 2024-09-24 | The Brigham And Women's Hospital, Inc. | Vero cell lines stably expressing HSV ICP0 protein |
-
2016
- 2016-10-21 BR BR112018008090A patent/BR112018008090A2/pt not_active Application Discontinuation
- 2016-10-21 PE PE2018000600A patent/PE20181531A1/es unknown
- 2016-10-21 AU AU2016342049A patent/AU2016342049B2/en active Active
- 2016-10-21 MX MX2018004918A patent/MX2018004918A/es unknown
- 2016-10-21 EA EA201890999A patent/EA201890999A1/ru unknown
- 2016-10-21 SG SG11201803365RA patent/SG11201803365RA/en unknown
- 2016-10-21 JP JP2018541090A patent/JP2018536023A/ja active Pending
- 2016-10-21 CN CN201680075061.1A patent/CN108472355A/zh active Pending
- 2016-10-21 MA MA046024A patent/MA46024A/fr unknown
- 2016-10-21 KR KR1020187014340A patent/KR20180096593A/ko unknown
- 2016-10-21 EP EP16858403.5A patent/EP3365009A4/fr active Pending
- 2016-10-21 WO PCT/US2016/058322 patent/WO2017070623A1/fr active Application Filing
- 2016-10-21 CA CA3002822A patent/CA3002822A1/fr active Pending
- 2016-10-21 US US15/767,618 patent/US20180303929A1/en not_active Abandoned
- 2016-10-21 TN TNP/2018/000155A patent/TN2018000155A1/en unknown
-
2018
- 2018-04-20 PH PH12018500855A patent/PH12018500855A1/en unknown
- 2018-04-20 CL CL2018001056A patent/CL2018001056A1/es unknown
- 2018-04-22 IL IL258833A patent/IL258833A/en unknown
- 2018-05-21 CO CONC2018/0005258A patent/CO2018005258A2/es unknown
-
2021
- 2021-12-16 JP JP2021204272A patent/JP2022037134A/ja active Pending
-
2023
- 2023-08-17 AU AU2023216825A patent/AU2023216825A1/en active Pending
- 2023-10-04 US US18/481,204 patent/US20240173400A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20180096593A (ko) | 2018-08-29 |
| CA3002822A1 (fr) | 2017-04-27 |
| SG11201803365RA (en) | 2018-05-30 |
| PE20181531A1 (es) | 2018-09-26 |
| PH12018500855A1 (en) | 2018-10-29 |
| EP3365009A1 (fr) | 2018-08-29 |
| CL2018001056A1 (es) | 2018-10-19 |
| EP3365009A4 (fr) | 2019-07-03 |
| US20180303929A1 (en) | 2018-10-25 |
| BR112018008090A2 (pt) | 2018-11-13 |
| AU2016342049A1 (en) | 2018-06-07 |
| US20240173400A1 (en) | 2024-05-30 |
| TN2018000155A1 (en) | 2019-10-04 |
| WO2017070623A1 (fr) | 2017-04-27 |
| AU2023216825A1 (en) | 2023-09-07 |
| CO2018005258A2 (es) | 2018-11-22 |
| CN108472355A (zh) | 2018-08-31 |
| MX2018004918A (es) | 2019-04-01 |
| AU2016342049B2 (en) | 2023-05-18 |
| EA201890999A1 (ru) | 2018-12-28 |
| JP2018536023A (ja) | 2018-12-06 |
| IL258833A (en) | 2018-06-28 |
| JP2022037134A (ja) | 2022-03-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA49463A (fr) | Vaccin contre le virus de l'herpès simplex | |
| MA46024A (fr) | Vaccin contre le virus de l'herpès simplex | |
| MA46584A (fr) | Vaccin contre le cytomégalovirus humain | |
| HK1256169A1 (zh) | 傳染病疫苗 | |
| MA47787A (fr) | Vaccin contre le virus respiratoire syncytial | |
| MA46316A (fr) | Vaccin contre le cytomégalovirus humain | |
| MA50813A (fr) | Vaccins contre le virus d'epstein-barr | |
| HK1255847A1 (zh) | 針對乙型肝炎病毒的疫苗 | |
| MA46317A (fr) | Vaccin contre le virus respiratoire syncytial | |
| MA43762A (fr) | Vaccin contre le rsv | |
| MA47016A (fr) | Vaccins contre les virus respiratoires | |
| LT3405466T (lt) | Arilu pakeistieji pirimidinai, skirti naudoti gripo viruso infekcijos atveju | |
| EP3194595A4 (fr) | Segments d'arn viral utilisés en tant qu'agents immunomodulateurs et composants de vaccin | |
| HK1246659A1 (zh) | 口蹄疫疫苗 | |
| HK1258252A1 (zh) | 腺嘌呤綴合物化合物及其作為疫苗佐劑的用途 | |
| BR112017013009A2 (pt) | formulação de vírus herpes simplex congelada estável | |
| EP3515929A4 (fr) | Vaccins thérapeutiques contre le virus de l'hépatite b | |
| GB201520345D0 (en) | Herpes simplex viruses | |
| EP3500280A4 (fr) | Vaccins contre des virus | |
| EP3139745B8 (fr) | Vaccins contre les infections de l'herpès simplex génital | |
| HK1216988A1 (zh) | 用於治療單純皰疹病毒 型感染的治療性疫苗 | |
| GB201702193D0 (en) | Hepatitis E virus vaccine | |
| AU2016903295A0 (en) | Viral Vaccines | |
| GB201507529D0 (en) | Virus preparations |